
    
      Phase I/II, open, prospective clinical trial, historically controlled. Patients affected of
      metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors will be included. The
      patients will receive standard treatment and experimental treatment based on a cellular
      therapy with vaccination with autologous dendritic cells pulsed with tumor lysate. The
      immunization schedule includes 4 monthly vaccines, 4 bimonthly and quarterly remaining
      vaccines. The vaccines will be administered intradermally in combination with standard
      treatment for each type of tumor.
    
  